Does nexrutine inhibit cancer cell growth as a consequence of mitochondrial damage and mitophagy?
Our study revealed that autophagy plays an important role in the inhibition of cancer cell proliferation by Nexrutine.
Of patients with nonmetastatic BP RMS on IRS IV 82% survived 6 years. Bladder function was preserved in 55% (36/66) of event-free survivors. Of all patients entered on study 40% (36 of 88) survive event-free with apparently normal functioning bladders. More precise long-term evaluation of bladder and sexual function will require application of better tools such as urodynamic studies and validated patient surveys.